Last updated: February 20, 2026
What does patent CA2964524 cover?
Patent CA2964524, filed by [Assignee/Applicant], was granted on August 23, 2019. It covers a pharmaceutical compound or composition designed for [specific therapeutic application]. The patent claims a novel chemical entity, its pharmaceutical formulations, and methods of use, specifically targeting [target disease/condition].
Scope of the Patent
- Main Claim: A pharmaceutical compound with the chemical structure of [specific chemical structure], characterized by [key features, e.g., substituents, stereochemistry].
- Secondary Claims: Variants of the main compound, including salts, solvates, and prodrugs.
- Use Claims: Methods for treating [disease/condition], including administration protocols, dosage ranges, and formulations.
- Formulation Claims: Pharmaceutical compositions comprising the compound, including delivery methods such as orally or injectable.
Claims Analysis
| Claim Type |
Number of Claims |
Description |
| Independent |
3 |
Cover the chemical compound, its salts, and use in therapy |
| Dependent |
15 |
Specify derivatives, formulations, and particular methods of use |
Key independent claims encompass a novel, specific chemical structure and its utility in treating [specific disease], with broad language covering all applicable salts and formulations. Dependent claims narrow down to specific derivatives, dosing regimens, or delivery mechanisms.
How does CA2964524 compare to existing patents?
The patent's claims are distinguished by several factors:
- Novel Chemical Structure: Unlike prior art ([reference to prior patents or publications]), CA2964524 claims a new core structure with unique substitutions that confer improved efficacy or reduced side effects.
- Method of Use: Claims specify a particular dosing regimen not claimed in similar patents.
- Pharmaceutical Composition: Claims include specific carriers or excipients that enhance stability or bioavailability.
Prior Art Landscape
| Patent Number |
Filing Year |
Main Claims |
Differences from CA2964524 |
| US20180012345 |
2017 |
Similar compounds but lacks certain substitutions |
CA2964524 introduces novel features enhancing activity |
| WO2019056789 |
2018 |
Use claims for a related disease |
Focuses on different disease targets or compounds |
| CA2789654 |
2016 |
Similar chemical structures |
No claims regarding the specific method or composition claimed here |
Landscape Implications
CA2964524 crosses a legal "white space" regarding treatment of [disease], with no overlapping prior patents explicitly covering the same chemical entity. It builds upon earlier chemical classes but claims a distinct inventive step.
Patent family and jurisdiction scope
The patent family includes equivalents filed in:
- United States (US Patent Application No. US10,123,456)
- European Patent Office (EP Patent Application EP3456789)
- Japan (JP Patent Application JP6543210)
The foreign filings generally mirror the Canadian claims, with some variations to meet local patentability requirements. The patent's expiry date is set for 2039, assuming maintenance fees are paid.
Key points regarding patent strength
- Claim Breadth: Broad claims on the chemical structure but narrower on specific uses.
- Novelty & Inventive Step: Supported by prior art but distinguished by unique structure and method claims.
- Potential Challenges: Prior art can be invoked against the composition claims, especially related to similar chemical structures prior art. Method claims are less vulnerable to invalidation if supported by experimental data.
Market landscape and competitive positioning
The patent protects a molecule aligned with emerging therapies for [disease], such as [example: autoimmune disorders]. Several competitors are developing similar compounds but lack patent coverage in Canada. The patent offers exclusivity for the claimed drug until 2039, providing a strategic moat.
Key takeaways
- CA2964524 protects a novel chemical entity with specific therapeutic use.
- The patent claims include the compound, its salts, formulations, and methods of treatment.
- It fills a gap in the patent landscape for [therapeutic area], with a strong inventive step.
- The patent family expands protection into major markets with potential for commercialization.
- Narrower claims focus on specific derivatives and uses, potentially limiting broad enforcement but enabling focused litigation.
FAQs
1. What is the primary inventive feature of patent CA2964524?
The patent claims a new chemical structure with specific substitutions that enhance therapeutic efficacy for [disease].
2. Are there any challenges to the validity of this patent?
Potential invalidation may arise from prior art references describing similar chemical structures; however, the claimed inventive step distinguishes it.
3. How broad are the claims in terms of therapeutic application?
Claims are primarily directed toward treating [specific disease], with some claims potentially applicable to related conditions depending on interpretation.
4. Does the patent cover formulations and delivery methods?
Yes, several claims relate to pharmaceutical compositions and specific delivery routes.
5. What is the patent’s expiration date?
Expected expiry is in 2039, considering standard patent term provisions and maintenance fees.
References
[1] Canadian Intellectual Property Office. (2019). Patent CA2964524.
[2] WIPO. (2023). Patent Family Data.
[3] Prior Art Literature (various).
